【摘要】 目的监测慢性阻塞性肺病急性发作(AECOPD)患者不动杆菌感染的耐药现状,评估头孢吡肟的耐药率。方法采取2002年1月～2005年12月AECOPD患者的痰标本,用全自动VITEK32仪对136株不动杆菌进行分析。结果对不动杆菌耐药率最低的抗生素,2002年(n=30)是阿米卡星和头孢吡肟(6.67%),2003年(n=32)是头孢吡肟和头孢哌酮/舒巴坦(3.12%),2004年(n=34)是头孢吡肟和亚胺培南(5.89%),2005年(n=40)是亚胺培南和头孢吡肟(2.50%)。结论不动杆菌是AECOPD常见的感染细菌,监测其耐药性可提供早期治疗和控制AECOPD患者的用药依据;治疗不动杆菌感染首选头孢吡肟,次选亚胺培南。更多还原

【Abstract】 Objective To monitor drug resistance of acinetobacter from acute exacerbation of chronic obstructive pulmonary disease (AECOPD),and to analyse the antibiotic resistance of cefepime.Methods To collect the sputum samples of AECOPD,and to use automatic VITEK 32 to analyze 136 strains of acinetobacter.Results Amikacinum and cefepime had the lowest antibiotic resistance(6.67%) in 30 strains acinetobacter separated in 2002.While in 2003,cefepime and cefoperazone sodium/sulbactam had the lowest rate(3.12%).Cefepime and imipenem/cilaztatin sodium had the lowest rate (5.89%)in 2004.Imipenem/cilaztatin and cefepime had the lowest antibiotic resistance in 2005(2.50%).Conclusion Acinetobacter is the common infection bacteria in AECOPD.Therefore,monitoring its antibiotic resistance can provide early,effectively therapy for the patients with acinetobacter infection.Cefepime is the best choice,imipenem being the second,for treating infection caused by acinetobacter.更多还原